1.888.443.3311

Clarient facebook  Clarient Twitter

 

  Search
 

PATHSiTE LOG IN


PATHSiTE® is our web-based solution with applications to help you view and manage your cases.
Learn more PATHSiTE Log In
bufferMedia
Clarient Diagnostic Services
Learn how we process cases
Learn how we process cases

 

Clarient Diagnostic Services

Learn how we process cases
 

ASCO - Annual Meeting 2013

 

Clarient InsightDx Mammostrat

 

Reduce your patient’s anxiety with test results available in days… not weeks. Clarient’s InsightDx Mammostrat provides important information independent of proliferation and grade to aid physicians in making appropriate and earlier treatment decisions in order to determine which patients are most likely to recur from breast cancer. Learn more

ALK Break Apart by FISH Testing at Clarient in NSCLC

Clarient performs ALK testing on all non-small cell lung cancer specimens that are paraffin embedded, including FNAs. Clarient follows the FDA approved kit guidelines.

Learn More

ALK-BreakAPart
ALK-BreakAPart


The Vysis ALK Break Apart FISH Probe Kit Intended Use1:


The Vysis ALK Break Apart FISH Probe Kit is a quantitative test to detect rearrangements involving the ALK gene via fluorescence in situ hybridization (FISH) in formalin-fixed paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tissue specimens to aid in identifying those patients eligible for treatment with XALKORI (crizotinib). This test is for prescription use only.”

For more information, please contact your local sales representative or call Clarient Client Services at 1-888-443-3311.

References:

  1. Vysis ALK Break Apart FISH Probe Kit. Package Insert. Des Plaines, IL: Abbott Molecular Inc.: 2011.

Is my cancer different

New from Clarient in breast cancer testing!
INFORM HER2 Dual ISH DNA Probe Test, FDA approved for determining eligibility for Herceptin® (trastuzumab) therapy in HER2 positive breast cancer patients.

Learn more        
buffer

therascreen® KRAS RGQ PCR testing for metastatic Colorectal cancer
Clarient now offers the only FDA approved KRAS test (therascreen® KRAS test), for use with ERBITUX® for patients with metastatic colorectal cancer. 

Learn more